| Literature DB >> 32531893 |
Virginia Prieto-Gómez1, Beatriz Navarro-Brazález1, Óscar Sánchez-Méndez1, Pedro de-la-Villa1, Beatriz Sánchez-Sánchez1, María Torres-Lacomba1.
Abstract
Certain secondary effects derived from medical treatment in breast cancer can favor the development of alterations in shoulder biomechanics. To the best of our knowledge, persistent peripheral pain as a key factor for the development of neuromuscular activity impairments has not been analyzed. A cross-sectional descriptive study was carried out. A total of 90 women were included and allocated to three groups: (i) 30 women with persistent peripheral pain after breast cancer treatment, (ii) 30 women without pain after breast cancer treatment, and (iii) 30 healthy women. Surface electromyography was employed to measure the onset and amplitude of the muscle activity of three shoulder movements. Statistically significant differences were found in the neuromuscular activity for all the muscles and shoulder movements among women with persistent pain versus healthy women (i.e., amplitude muscle activity variable p < 0.001). Statistically significant differences were also observed in the neuromuscular activity for certain muscles in shoulder movements among women with persistent pain versus women without pain, as well as between women without pain versus healthy women. Therefore, following breast cancer treatment, women showed alterations in their shoulder neuromuscular activity, which were more significant if persistent pain existed. These findings may contribute to developing a selective therapeutic exercise program that optimizes the shoulder neuromuscular activity in women after breast cancer treatment.Entities:
Keywords: breast cancer; electromyography; neuromuscular activity; persistent pain; shoulder motion
Year: 2020 PMID: 32531893 PMCID: PMC7355794 DOI: 10.3390/jcm9061804
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Figure 1Posterior view of electromyography electrodes position during isometric shoulder abduction contraction. The reference electrodes are indicated with a circle. Image of Prieto Gómez reproduced with permission of the participant; 2019.
Figure 2Anterior view of electromyography electrodes position during isometric shoulder abduction contraction. The reference electrodes are indicated with a circle. Image of Prieto Gómez reproduced with permission of the participant; 2019.
Demographic, anthropometric, therapeutic, and clinical outcomes.
| Outcomes | Group 1 | Group 2 | Group 3 |
|
|---|---|---|---|---|
|
| 56 (8) | 54 (8) | 55 (8) | 0.788 * |
|
| 25.4 (5.1) | 24.4 (5) | 23.5 (4.2) | 0.283 * |
|
| ||||
| Remunerated job ( | 12 (40) | 9 (30) | 10 (33.3) | 0.484 ** |
| Retired ( | 9 (30) | 15 (50) | 10 (33.3) | |
| Disable ( | 3 (10) | 0 | 2 (6.7) | |
| Jobless ( | 6 (20) | 6 (20) | 8 (26.7) | |
|
| ||||
| No studies ( | 3 (10) | 7 (23) | 1 (3.3) | 0.156 ** |
| Primary ( | 9 (30) | 8 (26.7) | 10 (33.3) | |
| Secondary ( | 6 (20) | 10 (33.3) | 9 (30) | |
| Bachelor ( | 8 (26.7) | 4 (13.3) | 10 (33.3) | |
| Superior grade ( | 3 (10) | 1 (3.3) | 0 | |
| Master/doctorate ( | 1 (3.3) | 0 | 0 | |
|
| ||||
| Lumpectomy ( | 26 (86.7) | 24 (80) | - | 0.488 ** |
| Quadrantectomy ( | 4 (13.3) | 6 (20) | ||
|
| ||||
| Lymphadenectomy ( | 29 (96.7) | 29 (96.7) | - | - |
| SNLB ( | 1 (3.3) | 1 (3.3) | ||
|
| 30 (100) | 30 (100) | - | - |
|
| 30 (100) | 30 (100) | - | - |
|
| 25 (83.3) | 23 (76.7) | - | 0.784 ** |
|
| 28 (93.3) | 29 (96.7) | - | NS ** |
|
| 1 (3.3) | 2 (6.7) | - | NS ** |
|
| 30 (100) | - | ||
|
| 7.20 (1.12) | |||
|
| ||||
| Predominant neuropathic pain ( | 25 (83.3) | - | ||
| Mix (neuropathic & nociceptive pain) ( | 30 (100) | |||
* test ANOVA; ** Chi-squared test. X: mean; SD: standard deviation; N/n: number; BMI: body max index; SLNB: sentinel lymph node biopsy; MPS: myofascial pain syndrome; VAS: visual analogue scale; NS: no significance (p > 0.999).
Figure 3Summary data of shoulder muscle activity in women after breast cancer treatment.
The onset of muscle activity. Abduction movement.
| Mm | Group 1 | Group 2 | Group 3 | Group 1 vs. Group 2 | Group 1 vs. Group 3 | Group 2 vs. Group 3 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dif | 95% CI | Dif | 95% CI | Dif | 95% CI | |||||||||||
| LL | UL | LL | UL | LL | UL | |||||||||||
|
|
|
|
|
|
|
|
|
|
| 0.26 | 1.94 |
| 0.04 | −0.79 | 0.88 | NS *** |
|
| −0.23 (0.2) | 0.16 (0.69) | 1.12 (0.09) |
| 0.40 | 0.13 | 0.66 |
| 1.35 | 1.09 | 1.62 |
| 0.95 | 0.69 | 1.22 |
|
|
| 1.85 (0.86) | 0.76 (0.65) | 0.22 (0.15) |
| 1.09 | 0.69 | 1.49 |
| 1.62 | 1.23 | 2.02 |
| 0.53 | 0.13 | 0.93 |
|
|
| 1.01 (1.81) | 0.90 (0.27) | −0.10 (1.13) |
| 0.10 | −0.67 | 0.89 | NS *** | 1.12 | 0.33 | 1.90 |
| 1.01 | 0.23 | 1.80 |
|
|
| 2.08 (1.08) | 1.15 (0.54) | 1.09 (0.21) |
| 0.93 | 0.48 | 1.38 |
| 0.99 | 0.54 | 1.44 |
| 0.06 | −0.38 | 0.50 | NS *** |
* ANOVA Test; ** Bonferroni test; *** p > 0.999. Mm (muscles); UT (upper trapezius); LT (lower trapezius), MD (middle deltoid), I (infraspinatus), SA (serratus anterior); X (mean); SD (standard deviation); Dif X (mean difference); 95% CI (95% confidence interval); LL (lower limit); UL (upper limit); NS (no significance); bold data = p < 0.005.
Onset of muscle activity. Flexion movement.
| Mm | Group 1 | Group 2 | Group 3 | Group 1 vs. Group 2 | Group 1 vs. Group 3 | Group 2 vs. Group 3 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dif | 95% CI | Dif | 95% CI | Dif | 95% CI | |||||||||||
| LL | UL | LL | UL | LL | UL | |||||||||||
|
|
|
|
|
|
|
|
|
|
| 0.13 | 0.32 |
| 0.03 | −0.13 | 0.05 | 0.924 |
|
| 0.59 (0.29) | 0.86 (0.3) | 0.98 (0.21) |
| 0.26 | 0.09 | 0.43 |
| 0.39 | 0.21 | 0.56 |
| 0.12 | 0.04 | 0.30 | 0.228 |
|
| 0.99 (0.61) | 0.24 (0.37) | 0.04 (0.14) |
| 0.74 | 0.48 | 1.01 |
| 0.95 | 0.68 | 1.22 |
| 0.20 | −0.05 | 0.47 | 0.178 |
|
| 0.03 (0.18) | 0.19 (0.23) | 0.3 (0.26) |
| 0.15 | 0.01 | 0.3 |
| 0.26 | 0.12 | 0.41 |
| 0.11 | 0.03 | 0.25 | 0.204 |
|
| 1.25 (0.38) | 0.75 (0.36) | 0.51 (0.3) |
| 0.50 | 0.27 | 0.72 |
| 0.74 | 0.52 | 0.96 |
| 0.24 | 0.02 | 0.46 |
|
* ANOVA Test. ** Bonferroni test. Mm (muscles); UT (upper trapezius); LT (lower trapezius), AD (anterior deltoid), I (infraspinatus), SA (serratus anterior); X (mean); SD (standard deviation); Dif X (mean difference); 95% CI (95% confidence interval); LL (lower limit); UL (upper limit); bold data = p < 0.05.
Onset of muscle activity. External rotation movement.
| Mm | Group 1 | Group 2 | Group 3 | Group 1 vs. Group 2 | Group 1 vs. Group 3 | Group 2 vs. Group 3 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dif | 95% CI | Dif | 95% CI | Dif | 95% CI | |||||||||||
| LL | UL | LL | UL | LL | UL | |||||||||||
|
|
|
|
|
|
|
|
|
|
| 0.05 | 0.32 |
| 0.08 | 0.05 | 0.31 | 0.453 |
|
| 2.01 (0.74) | 1.5 (0.46) | 1.49 (0.36) |
| 0.45 | 0.10 | 0.79 |
| 0.52 | 0.17 | 0.86 |
| 0.06 | −0.27 | 0.41 | NS *** |
|
| 0.82 (0.47) | 0.67 (0.38) | 0.46 (0.29) |
| 0.15 | −0.09 | 0.40 | 0.378 | 0.36 | 0.11 | 0.61 |
| 0.20 | −0.03 | 0.45 | 0.129 |
|
| 0.29 (0.52) | 0.11 (0.36) | −0.03 (0.08) |
| 0.18 | −0.05 | 0.41 | 0.177 | 0.33 | 0.10 | 0.56 |
| 0.15 | −0.08 | 0.38 | 0.340 |
|
| 1.68 (0.54) | 1.29 (0.54) | 1.04 (0.33) |
| 0.39 | 0.08 | 0.69 |
| 0.64 | 0.33 | 0.94 |
| 0.24 | −0.05 | 0.55 | 0.154 |
* ANOVA Test **; Bonferroni test ***; p > 0.999. Mm (muscles); UT (upper trapezius); LT (lower trapezius), PD (posterior deltoid), I (infraspinatus), SA (serratus anterior); X (mean); SD (standard deviation); Dif X (mean difference); 95% CI (95% confidence interval); UL (upper limit); LL (lower limit); NS (no significance); bold data: p < 0.05.
The amplitude of muscle activity (RMS%). Abduction movement.
| Mm | Group 1 | Group 2 | Group 3 | Group 1 vs. Group 2 | Group 1 vs. Group 3 | Group 2 vs. Group 3 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dif | 95% CI | Dif | 95% CI | Dif | 95% CI | |||||||||||
| LL | UL | LL | UL | LL | UL | |||||||||||
|
|
|
|
|
|
|
|
|
|
| 17.21 | 31.04 |
| 4.39 | −2.52 | 11.30 | 0.374 |
|
| 14.72 (5.37) | 15.94 (3.85) | 19.64 (4.30) |
| 1.21 | 1.65 | 4.09 | 0.909 | 4.92 | 2.04 | 7.79 |
| 3.70 | 0.83 | 6.57 |
|
|
| 75.41 (10.19) | 65.97 (9.89) | 59.74 (8.86) |
| 9.44 | 3.35 | 15.54 |
| 15.67 | 9.58 | 21.77 |
| 6.23 | 0.13 | 12.32 |
|
|
| 6.52 (2.63) | 10.07 (3.01) | 10.99 (3.27) |
| 3.55 | 1.67 | 5.43 |
| 4.47 | 2.59 | 6.35 |
| 0.92 | −2.8 | 0.96 | 0.709 |
|
| 4.75 (2.25) | 13.77 (5.9) | 22.63 (5.31) |
| 9.02 | 6.01 | 12.02 |
| 17.87 | 14.87 | 20.87 |
| 8.85 | 5.85 | 11.85 |
|
* ANOVA Test; ** Bonferroni test. Mm (muscles); UT (upper trapezius); LT (lower trapezius), MD (middle deltoid), I (infraspinatus), SA (serratus anterior); X (mean); SD (standard deviation); Dif X (mean difference); 95% CI (95% confidence interval); LL (lower limit); UL (upper limit); bold data: p < 0.05.
The amplitude of muscle activity (RMS%). Flexion movement.
| Mm | Group 1 | Group 2 | Group 3 | Group 1 vs. Group 2 | Group 1 vs. Group 3 | Group 2 vs. Group 3 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dif | 95% CI | Dif | 95% CI | Dif | 95% CI | |||||||||||
| LL | UL | LL | UL | LL | UL | |||||||||||
|
|
|
|
|
|
|
|
|
|
| 14.87 | 24.55 |
| 3.57 | −1.27 | 8.41 | 0.226 |
|
| 11.21 (3.99) | 15.24 (4.36) | 22.89 (7.68) |
| 4.03 | 0.50 | 7.56 |
| 11.68 | 8.14 | 15.21 |
| 7.64 | 4.11 | 11.17 |
|
|
| 80.79 (9.68) | 65.43 (13.70) | 61.90 (12.17) |
| 15.35 | 7.8 | 22.89 |
| 18.89 | 11.34 | 26.43 |
| 3.53 | −4.008 | 11.08 | 0.767 |
|
| 11.17 (5.67) | 22.6 (12.41) | 46.88 (11.49) |
| 11.42 | 4.93 | 12.92 |
| 35.70 | 29.21 | 42.2 |
| 24.28 | 17.78 | 30.77 |
|
|
| 6.8 (3.54) | 17.32 (7.7) | 38.23 (11.04) |
| 10.45 | 5.39 | 15.52 |
| 31.36 | 26.30 | 36.43 |
| 20.91 | 15.84 | 25.97 |
|
* ANOVA Test; ** Bonferroni test. Mm (muscles); UT (upper trapezius); LT (lower trapezius), AD (anterior deltoid), I (infraspinatus), SA (serratus anterior); X (mean); SD (standard deviation); Dif X (mean difference); 95% CI (95% confidence interval); LL (lower limit); UL (upper limit); bold data = p < 0.05.
The amplitude of muscle activity (RMS%). External rotation movement.
| Mm | Group 1 | Group 2 | Group 3 | Group 1 vs. Group 2 | Group 1 vs. Group 3 | Group 2 vs. Group 3 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dif | 95% CI | Dif | 95 % CI | Dif | 95% CI | |||||||||||
| LL | UL | LL | UL | LL | UL | |||||||||||
|
|
|
|
|
|
|
|
|
|
| 9.57 | 19.82 |
| 3.56 | −1.56 | 8.68 | 0.281 |
|
| 17.14 (3.71) | 28.84 (12.39) | 32.57 (12.1) |
| 11.7 | 5.25 | 18.15 |
| 15.43 | 8.98 | 21.88 |
| 3.73 | −10.17 | 2.71 | 0.484 |
|
| 22.39 (7.48) | 42.81 (16.95) | 48.5 (12.02) |
| 20.42 | 12.38 | 28.46 |
| 26.11 | 18.07 | 34.14 |
| 5.68 | −13.72 | 2.35 | 0.263 |
|
| 20.91 (7.34) | 50.20 (20.73) | 72.55 (8.62) |
| 29.29 | 20.69 | 37.89 |
| 51.64 | 43.02 | 60.24 |
| 22.35 | 13.75 | 30.94 |
|
|
| 17.09 (6.60) | 28.67 (10.75) | 59.86 (10.92) |
| 11.58 | 5.5 | 17.65 |
| 42.77 | 36.69 | 48.84 |
| 31.19 | 25.11 | 37.26 |
|
* ANOVA Test; ** Bonferroni test. Mm (muscles); UT (upper trapezius); LT (lower trapezius), PD (posterior deltoid), I (infraspinatus), SA (serratus anterior); X (mean); SD (standard deviation); Dif X (mean difference); 95% CI (95% confidence interval); LL (lower limit); UL (upper limit); bold data: p < 0.05.